NCT05576961 2024-01-23
Safety and Efficacy of RX-af01 Combined With PD-1 Antibody
Sun Yat-sen University
Phase 1/2 Unknown
Clinical Trials
14 trialsNCT05580445 2023-11-22
Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
Shouyao Holdings (Beijing) Co. LTD
Phase 1/2 Unknown
NCT04856631 2022-12-19
A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT03864211 2022-09-29
Thermal Ablation Followed by Immunotherapy for HCC
Xiangya Hospital of Central South University
Phase 1/2 Unknown
NCT05341193 2022-04-22
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 1/2 Unknown
NCT04058470 2022-04-14
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Sun Yat-sen University
Phase 1/2 Unknown
NCT05173142 2022-03-08
HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors
Hutchmed
Phase 1/2 Unknown
NCT02915432 2021-12-13
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT05103917 2021-11-02
A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC
Abbisko Therapeutics Co, Ltd
Phase 1/2 Unknown
NCT04926532 2021-06-15
Toripalimab
Shanghai Zhongshan Hospital
Phase 1/2 Unknown
NCT04797702 2021-03-15
CT32
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT04368273 2020-04-29
CCRT+PD-1
Peking University Third Hospital
Phase 1/2 Unknown
NCT04069949 2019-10-25
STUHCCPVTT
Sichuan University
Phase 1/2 Unknown
NCT04061928 2019-08-20
Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ
Peking University
Phase 1/2 Unknown